JP2024167313A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024167313A5 JP2024167313A5 JP2024146208A JP2024146208A JP2024167313A5 JP 2024167313 A5 JP2024167313 A5 JP 2024167313A5 JP 2024146208 A JP2024146208 A JP 2024146208A JP 2024146208 A JP2024146208 A JP 2024146208A JP 2024167313 A5 JP2024167313 A5 JP 2024167313A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- variable region
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 28
- 210000004027 cell Anatomy 0.000 claims 10
- 239000000427 antigen Substances 0.000 claims 8
- 102000036639 antigens Human genes 0.000 claims 8
- 108091007433 antigens Proteins 0.000 claims 8
- 102000002029 Claudin Human genes 0.000 claims 2
- 108050009302 Claudin Proteins 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 101710112752 Cytotoxin Proteins 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 239000002619 cytotoxin Substances 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910315634 | 2019-04-19 | ||
| CN201910315634.9 | 2019-04-19 | ||
| JP2021562118A JP2022529703A (ja) | 2019-04-19 | 2020-04-15 | 腫瘍治療薬及びその応用 |
| PCT/CN2020/084991 WO2020211792A1 (zh) | 2019-04-19 | 2020-04-15 | 肿瘤治疗剂及其应用 |
| JP2023129054A JP7547581B2 (ja) | 2019-04-19 | 2023-08-08 | 腫瘍治療薬及びその応用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023129054A Division JP7547581B2 (ja) | 2019-04-19 | 2023-08-08 | 腫瘍治療薬及びその応用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024167313A JP2024167313A (ja) | 2024-12-03 |
| JP2024167313A5 true JP2024167313A5 (enExample) | 2025-04-17 |
Family
ID=72837018
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021562118A Pending JP2022529703A (ja) | 2019-04-19 | 2020-04-15 | 腫瘍治療薬及びその応用 |
| JP2023129054A Active JP7547581B2 (ja) | 2019-04-19 | 2023-08-08 | 腫瘍治療薬及びその応用 |
| JP2024146208A Pending JP2024167313A (ja) | 2019-04-19 | 2024-08-28 | 腫瘍治療薬及びその応用 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021562118A Pending JP2022529703A (ja) | 2019-04-19 | 2020-04-15 | 腫瘍治療薬及びその応用 |
| JP2023129054A Active JP7547581B2 (ja) | 2019-04-19 | 2023-08-08 | 腫瘍治療薬及びその応用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220372112A1 (enExample) |
| EP (1) | EP3960766A4 (enExample) |
| JP (3) | JP2022529703A (enExample) |
| CN (2) | CN119613553A (enExample) |
| WO (1) | WO2020211792A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210134321A (ko) | 2019-02-01 | 2021-11-09 | 노바록 바이오테라퓨틱스 리미티드 | 항-클라우딘 18 항체 및 이의 이용 방법 |
| CN114366818B (zh) * | 2020-10-15 | 2025-02-25 | 上海美雅珂生物技术有限责任公司 | 抗体药物偶联物及其应用 |
| EP4299593A4 (en) * | 2021-04-02 | 2025-12-10 | Oricell Therapeutics Co Ltd | CLDN18.2 ANTIGEN-BINDING PROTEIN AND ITS USE |
| WO2023078386A1 (zh) | 2021-11-05 | 2023-05-11 | 正大天晴药业集团股份有限公司 | 抗cldn18.2抗体及其用途 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| TW202530228A (zh) | 2023-10-12 | 2025-08-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025086270A1 (en) | 2023-10-27 | 2025-05-01 | Keymed Biosciences (Chengdu) Co., Ltd. | Cancer treatment with anti-claudin 18.2 adc |
| WO2025086268A1 (en) | 2023-10-27 | 2025-05-01 | Keymed Biosciences (Chengdu) Co., Ltd. | Cancer treatment with anti-claudin 18.2 adc |
| TW202535476A (zh) | 2023-10-27 | 2025-09-16 | 大陸商康諾亞生物醫藥科技（成都）有限公司 | 使用抗密連蛋白１８．２ ａｄｃ之癌症治療 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7229619B1 (en) | 2000-11-28 | 2007-06-12 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
| WO2013167153A1 (en) * | 2012-05-09 | 2013-11-14 | Ganymed Pharmaceuticals Ag | Antibodies useful in cancer diagnosis |
| NZ746691A (en) * | 2012-11-13 | 2020-08-28 | Astellas Pharma Inc | Agents for treatment of claudin expressing cancer diseases |
| WO2014127785A1 (en) * | 2013-02-20 | 2014-08-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| ES2979068T3 (es) * | 2016-07-08 | 2024-09-24 | Crage Medical Co Ltd | Anticuerpos para anti-claudina 18A2 y utilización de los mismos |
-
2020
- 2020-04-15 EP EP20791781.6A patent/EP3960766A4/en active Pending
- 2020-04-15 US US17/604,735 patent/US20220372112A1/en active Pending
- 2020-04-15 WO PCT/CN2020/084991 patent/WO2020211792A1/zh not_active Ceased
- 2020-04-15 CN CN202411010644.9A patent/CN119613553A/zh active Pending
- 2020-04-15 JP JP2021562118A patent/JP2022529703A/ja active Pending
- 2020-04-15 CN CN202080028880.7A patent/CN113748133B/zh active Active
-
2023
- 2023-08-08 JP JP2023129054A patent/JP7547581B2/ja active Active
-
2024
- 2024-08-28 JP JP2024146208A patent/JP2024167313A/ja active Pending